SLC2A1 and neoplasm: AST has been demonstrated to reduce the mRNA expression levels of c-Myc and glycolytic enzymes (LDH-A, Glut-1, and HK2) in a DSS-induced mouse model, suggesting its potential for combating tumor-associated inflammation and maintaining normal glucose homeostasis [152].